What are the diagnostic criteria and first-line management for cerebral salt‑wasting syndrome?

Cerebral Salt Wasting Syndrome: Diagnostic Criteria and First-Line Management

Diagnostic Criteria

Cerebral salt wasting (CSW) is diagnosed by the triad of hyponatremia, clinical hypovolemia, and inappropriately elevated urinary sodium excretion in patients with central nervous system pathology. 1, 2, 3, 4

Essential Diagnostic Features

• Hyponatremia: Serum sodium <135 mmol/L, with investigation warranted when levels fall below 131 mmol/L 1, 2
• Clinical hypovolemia: Orthostatic hypotension, tachycardia, dry mucous membranes, decreased skin turgor, flat neck veins, and central venous pressure <6 cm H₂O 1, 2, 4
• Inappropriately high urinary sodium: Typically >20 mmol/L despite volume depletion 1, 2, 4
• Elevated urine osmolality: High relative to serum osmolality 2
• Underlying CNS pathology: Most commonly subarachnoid hemorrhage, traumatic brain injury, neurosurgery, or bacterial meningitis 5, 3, 6

Critical Distinction from SIADH

The cornerstone of differentiating CSW from SIADH is volume status assessment—CSW presents with true hypovolemia while SIADH is euvolemic. 1, 2, 3, 4 This distinction is absolutely critical because the treatments are diametrically opposed: CSW requires aggressive volume and sodium replacement, whereas SIADH requires fluid restriction. 1, 2, 3

Key differentiating features:

• CSW: CVP <6 cm H₂O, clinical signs of volume depletion, urine sodium >20 mmol/L despite hypovolemia 1, 2, 4
• SIADH: CVP 6-10 cm H₂O, euvolemic state (no edema, no orthostatic hypotension, normal skin turgor, moist mucous membranes), urine sodium >20-40 mmol/L, urine osmolality >300 mOsm/kg 1, 7

High-Risk Populations

• Poor clinical grade subarachnoid hemorrhage patients 2
• Ruptured anterior communicating artery aneurysms 2
• Patients with hydrocephalus 2
• Traumatic brain injury survivors 8, 6

---

First-Line Management

The primary treatment of CSW is aggressive volume and sodium replacement with isotonic or hypertonic saline—fluid restriction is absolutely contraindicated and will worsen outcomes. 1, 2, 3, 4

Immediate Treatment Protocol

For severe symptomatic hyponatremia (seizures, altered mental status):

• Administer 3% hypertonic saline with initial goal to correct 6 mmol/L over 6 hours or until severe symptoms resolve 1, 2, 7
• ICU admission for close monitoring with serum sodium checks every 2 hours initially 1, 2
• Maximum correction limit: Never exceed 8 mmol/L in any 24-hour period to prevent osmotic demyelination syndrome 1, 2, 4

For moderate CSW without severe neurological symptoms:

• Isotonic saline (0.9% NaCl) at 50-100 mL/kg/day for volume repletion 2, 4
• Hypertonic saline (3%) may be required for substantial sodium deficits 2, 8, 4
• Target CVP: 8-12 cm H₂O to confirm adequate volume restoration 1

Adjunctive Pharmacological Therapy

Fludrocortisone (0.1-0.2 mg daily) should be considered as adjunctive therapy, particularly in severe or refractory CSW. 1, 2, 8, 4

• Mechanism: Mineralocorticoid that reduces renal sodium losses 2, 8, 4
• Evidence: Class I recommendation for subarachnoid hemorrhage patients at risk of vasospasm 1
• Benefit: Reduces the volume of hypertonic saline required and helps maintain serum sodium levels 8

Hydrocortisone may be used to prevent natriuresis in subarachnoid hemorrhage patients (Class I recommendation). 1 Studies showed hydrocortisone 1200 mg/day for 10 days prevented hyponatremia development (0% vs 43% in controls), maintained targeted serum sodium levels, and reduced urine volume. 1

Special Considerations for Subarachnoid Hemorrhage

In SAH patients at risk of vasospasm, hyponatremia should NEVER be treated with fluid restriction. 1, 2 This is a Class II recommendation because fluid restriction can precipitate cerebral ischemia. 1, 2 Instead:

• Aggressive volume resuscitation with crystalloid or colloid agents ameliorates the risk of cerebral ischemia 2
• Hypertonic saline increases regional cerebral blood flow, brain tissue oxygen, and pH in high-grade SAH 2
• Fludrocortisone and hydrocortisone should be considered to prevent vasospasm 1, 2

Monitoring Requirements

• Serum sodium: Every 2 hours during initial correction for severe symptoms; every 4 hours after symptom resolution 1, 2
• Volume status: Clinical assessment of orthostatic vitals, skin turgor, mucous membranes, CVP if available 1, 2, 4
• Urine output and sodium: Monitor ongoing renal losses to guide replacement therapy 2, 4
• Watch for osmotic demyelination syndrome: Dysarthria, dysphagia, oculomotor dysfunction, quadriparesis typically occurring 2-7 days after rapid correction 1, 2

---

Critical Pitfalls to Avoid

The most dangerous error is misdiagnosing CSW as SIADH and applying fluid restriction—this worsens hypovolemia, precipitates cerebral ischemia, and leads to catastrophic outcomes. 1, 2, 3, 6

• Never use fluid restriction in CSW as it can worsen outcomes and increase vasospasm risk 1, 2
• Never correct sodium faster than 8 mmol/L in 24 hours to prevent osmotic demyelination syndrome 1, 2, 4
• Never ignore volume status assessment—physical examination alone has poor sensitivity (41.1%) and specificity (80%), so use CVP and clinical context 1, 2
• Never delay treatment while waiting for ADH or natriuretic peptide levels, as obtaining these is not supported by evidence 1, 2

Pathophysiology Note

CSW is produced by excessive secretion of natriuretic peptides causing hyponatremia through excessive natriuresis, which may also provoke volume contraction. 2, 4 This mechanism distinguishes it fundamentally from SIADH, where water retention is the primary problem. 3, 4